« Back to Directory of Resources
Treatments Under Development
Here you will find a list of current treatments under development:
| Brand Name: | |
| Generic Name: | milatuzumab |
| Code Name: | |
| Company: | Immunomedics, Inc. |
| FDA Clinical Phase: | 1/2 |
Description:
Milatuzumab is a humanized monoclonal antibody that targets tumors expressing the CD74 antigen. As the first anti-CD74 antibody studied in human clinical trials, …
| Brand Name: | Genasense |
| Generic Name: | oblimersen |
| Code Name: | G3139 |
| Company: | Genta, Inc. & Aventis |
| FDA Clinical Phase: | 3 |
Description:
Genasense is a type of antisense oligodeoxyribonucleotide. It may kill cancer cells by| Brand Name: | |
| Generic Name: | panobinostat |
| Code Name: | LBH589 |
| Company: | Novartis |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Panobinostat (news articles), which is a potent histone deacetylase (HDAC) inhibitor, selectively targets tumor cells for cell death. In Phase 1 trials, …
| Brand Name: | |
| Generic Name: | perifosine |
| Code Name: | KRX-0401 |
| Company: | Keryx Biopharmaceuticals / Aeterna Zentaris |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Perifosine (news articles) is a novel anti-cancer agent that is being studied for its ability to inhibit Akt, a …
| Brand Name: | Aplidin |
| Generic Name: | plitidepsin |
| Code Name: | |
| Company: | PharmaMar, SA |
| FDA Clinical Phase: | 3 |
Description:
Aplidin is derived from a compound found in tunicates which shows promise in shrinking tumors.| Brand Name: | |
| Generic Name: | pomalidomide |
| Code Name: | CC-4047, Actimid |
| Company: | Celgene |
| FDA Clinical Phase: | 1/2 |
Description:
Pomalidomide (new articles, forum discussions) is an immunomodulatory agent (a drug that affects the immune system) that encourages a patient’s immune system to attack and destroy myeloma cells.